3 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 3 |
Follow Nut and Peanut Hypersensitivity: new trials by email Literature Review of Nut and Peanut Hypersensitivity trials Research Report on Nut and Peanut Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Extension Study of Ligelizumab in Food Allergy Ligelizumab 120 mg, Ligelizumab 240 mg - Food Allergy | Phase 3 | Terminated | Novartis Pharmaceuticals | 163 | 2023-04-27 | 2026-01-13 |
| Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy ligelizumab, Placebo - Allergy, Peanut | Phase 3 | Terminated | Novartis Pharmaceuticals | 211 | 2021-12-07 | 2025-04-29 |
| Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents AR101 - Peanut Allergy | Phase 3 | Terminated | Aimmune Therapeutics, Inc. | 1 | 2018-10-24 | 2021-07-13 |
Peanut Hypersensitivity (3) · Food Hypersensitivity (2) · Hypersensitivity (1)
Hypersensitivity, Immediate (3) · Immune System Diseases (3) · Hypersensitivity (2) · Food Hypersensitivity (1)
ligelizumab (2)
Novartis Pharmaceuticals (2) · Aimmune Therapeutics, Inc. (1)
Spain (3) · Australia (2) · Canada (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · Netherlands (2) · United States (2) · Denmark (1)
2018 (1)